Abstract 865P
Background
The prognosis of early OSCC is strongly correlated with local disease control. However, patients with T1-T2 OSCC and clear margins have a 5-year local relapse rate of around 15%. The evaluation of the quality of surgical resection is therefore essential.
Methods
A prospective multicenter trial based on patients with T1-T2 OSCC treated surgically with clear margins, showed the interest of a molecular analysis (microsatellite instability (MSI)) of surgical margins to evaluate the minimal residual disease (MRD) while adapting the postoperative strategy (NCT00232960). Recently, innovative techniques for detecting circulating tumor DNA have been developed. Our main objective was, then, to evaluate the feasibility of detecting MRD by identifying specific molecular abnormalities with Whole Exom Sequencing (WES) and Shallow Whole Genome Sequencing (ShWGS) in the primary tumor and looking for it on the margins.
Results
310 patients were included initially with 216 tumor/margins samples available for molecular analysis. Tumor was informative for MSI analysis in 63% of cases (n=133). Positive molecular margins were observed in 23 cases, leading to a postoperative treatment. Median follow-up was 58 months [30;83]. In informative tumor, molecularly driven treatment seemed to lower the 5-year local recurrence rate from 14.1% to 6.4% (p=0.15). Among the initial cohort, 108 primary tumors were secondary screened by WES with an informative rate of 78.6%. With a 10X depth for molecular analysis, we observed 13 patients with at least one positive margin. Then, analyzing retrospectively the oncologic outcomes, we observed a significant benefit for local control at 5 years for patients with WES negative margins (91.7% versus 64.1%, p=0.02). We, then, performed a ShWGS analysis on a sub-group of 39 patients. Patients with positive margins both in WES and ShWGS had a higher risk of local relapse at 5 years (p<10-3).
Conclusions
Molecular analysis of surgical margins for early OSCC lead to a better assessment of microscopic residual disease while postoperative decision making according to WES and ShWGS could improve local control.
Clinical trial identification
NCT00232960.
Editorial acknowledgement
Legal entity responsible for the study
GETTEC group (French Group for Study of Head and Neck Tumors).
Funding
PHRC program from INCA (French National Cancer Institute) PRISM program from Gustave Roussy Cancer Campus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12
930P - Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Presenter: Marcelo Bonomi
Session: Poster session 12
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12